Tositumomab is a monoclonal anti-CD20 antibody used to treat B-cell non-Hodgkin's lymphoma via a conjugated radioactive isotope. Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues).
- Mechanism
- Curator reviewed
Binds to the CD20 antigen which is found on mature B lymphocytes. The antibody binding appears to induce apoptosis, complement-dependent cytotoxicity and cell death through ionizing radiation.
- Primary indication
- For treatment of non-Hodgkin's lymphoma (CD20 positive, follicular)Curator reviewed
- Formula / weight
- C6416H9874N1688O1987S44 · 143859.7 Da
- First approval
- Canada, 2005 · United States, 2009
Resolves to
Clinical / RWD
Targets
What you can answer from here — as of July 17, 2026
2Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Tositumomab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account